Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $97.44 million. The enterprise value is -$60.92 million.
Important Dates
The next estimated earnings date is Monday, November 11, 2024, after market close.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ORMP has 40.77 million shares outstanding. The number of shares has increased by 3.79% in one year.
| Shares Outstanding | 40.77M |
| Shares Change (YoY) | +3.79% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 9.01% |
| Owned by Institutions (%) | 11.90% |
| Float | 35.05M |
Valuation Ratios
The trailing PE ratio is 4.72.
| PE Ratio | 4.72 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 41.06, with a Debt / Equity ratio of 0.00.
| Current Ratio | 41.06 |
| Quick Ratio | 40.92 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.45 |
Financial Efficiency
Return on equity (ROE) is 12.70% and return on invested capital (ROIC) is -4.90%.
| Return on Equity (ROE) | 12.70% |
| Return on Assets (ROA) | -4.72% |
| Return on Capital (ROIC) | -4.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $1.60M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $1.63 million in taxes.
| Income Tax | 1.63M |
| Effective Tax Rate | 7.30% |
Stock Price Statistics
The stock price has increased by +33.52% in the last 52 weeks. The beta is 1.77, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.77 |
| 52-Week Price Change | +33.52% |
| 50-Day Moving Average | 2.39 |
| 200-Day Moving Average | 2.53 |
| Relative Strength Index (RSI) | 51.59 |
| Average Volume (20 Days) | 75,500 |
Short Selling Information
The latest short interest is 298,473, so 0.73% of the outstanding shares have been sold short.
| Short Interest | 298,473 |
| Short Previous Month | 340,413 |
| Short % of Shares Out | 0.73% |
| Short % of Float | 0.85% |
| Short Ratio (days to cover) | 3.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.87M |
| Pretax Income | 10.46M |
| Net Income | 20.86M |
| EBITDA | -12.65M |
| EBIT | -12.87M |
| Earnings Per Share (EPS) | $0.51 |
Full Income StatementBalance Sheet
The company has $152.74 million in cash and $486,000 in debt, giving a net cash position of $154.60 million or $3.79 per share.
| Cash & Cash Equivalents | 152.74M |
| Total Debt | 486,000 |
| Net Cash | 154.60M |
| Net Cash Per Share | $3.79 |
| Equity (Book Value) | 176.15M |
| Book Value Per Share | 4.36 |
| Working Capital | 149.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.51 million and capital expenditures -$37,000, giving a free cash flow of -$1.55 million.
| Operating Cash Flow | -1.51M |
| Capital Expenditures | -37,000 |
| Free Cash Flow | -1.55M |
| FCF Per Share | -$0.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -931.60% |